Sign In
Buy COYA
$4.19
+0.110 (+2.70%)
At Close: Jul 31, 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
05:17pm, Friday, 07'th Feb 2025
Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically com
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch
01:53pm, Friday, 07'th Feb 2025
Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data fro
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
01:30pm, Thursday, 06'th Feb 2025
On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients wi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
08:15am, Monday, 25'th Nov 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
08:00am, Wednesday, 06'th Nov 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
08:15am, Friday, 01'st Nov 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
10:31am, Thursday, 31'st Oct 2024
Coya Therapeutics, Inc.'s stock has sold off on misinterpreted data from a small trial with COYA 301. The presented clinical data validates safety, tolerability, and the inverse dose response of IL-2
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
02:36pm, Tuesday, 29'th Oct 2024
On Tuesday, Coya Therapeutics, Inc. COYA released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial
06:41am, Tuesday, 29'th Oct 2024
Coya Therapeutics said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with Alzheimer's disease enr
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
04:17am, Sunday, 13'th Oct 2024
Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reacti
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
09:15am, Tuesday, 08'th Oct 2024
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
